Indoco Remedies tumbled 8.60% to Rs 369.95 after the company's net profit declined 15% to Rs 27.9 crore despite an 18% rise in net revenues to Rs 410.6 crore in Q3 FY23 over Q3 FY22.
EBIDTA fell by 16% YoY to Rs 61.7 crore while EBIDTA margin contracted by 610 bps to 15% during the quarter.
Operating profit in Q3 FY23 stood at Rs 57.3 crore, down by 15% from Rs 67.5 crore in Q3 FY22.
Aditi Panandikar, managing director, Indoco Remedies, said, A good performance in domestic business and an excellent growth in export business has allowed us to post good results this quarter.
Indoco Remedies, headquartered in Mumbai, is a fully integrated, research-oriented pharma company with presence in 55 countries.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app